{"id":"W4399395213","doi":"10.1200/jco.2024.42.16_suppl.5595","title":"Durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer (EC) in DUO-E: Results by <i>BRCA1</i>/<i>BRCA2</i> mutation (BRCAm) status.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Durvalumab; Medicine; Paclitaxel; Carboplatin; Olaparib; Endometrial cancer; Oncology; Gynecology; Cancer; Internal medicine; Urology; Chemotherapy; Cisplatin; Immunotherapy; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001049622,0.0004891027,0.001192225,0.0002026016,0.0001930027,0.0004781409,0.0006030305,0.0004812617,0.003149357],"category_scores_gemma":[0.0007955746,0.0003282145,0.0007994632,0.0002708363,0.0004640181,0.0004036087,0.0002913917,0.001410215,0.0003617682],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007012659,"about_ca_system_score_gemma":0.001074392,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001167991,"about_ca_topic_score_gemma":0.005106018,"domain_scores_codex":[0.9996192,0.0001937095,0.00002569031,0.00005706738,0.0000241477,0.00008006575],"domain_scores_gemma":[0.9994026,0.0001688593,0.0001028719,0.00004364913,0.00001495077,0.000267184],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.9317288,0.0168435,0.005111847,0.0002815206,0.0006090822,0.0001007538,0.00007377219,0.0006857938,0.009568899,0.00008082633,0.0006298736,0.03428532],"study_design_scores_gemma":[0.3571475,0.6052423,0.02770715,0.00004909747,0.001217824,0.0002549312,0.00008649494,0.001185822,0.004825904,0.0001536556,0.002101471,0.00002775248],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.997465,0.0008284263,0.000111754,0.00008682198,0.00004984868,0.0005148359,0.0003346757,0.00001250046,0.0005961621],"genre_scores_gemma":[0.997274,0.000667621,0.0004040955,0.000135925,0.00004771875,0.0003788142,0.0004083797,0.000004122101,0.0006793874],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003149357,"threshold_uncertainty_score":0.01053566,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1265810777216307,"score_gpt":0.4967792795174652,"score_spread":0.3701982017958345,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}